The aim of this study was to evaluate the apoptotic damage to bone marrow cells caused by three chemotherapy regimens for advanced Hodgkin's lymphoma, ABVD, COPPEBVCAD and BEACOPP, which were randomly administered in the HD 2000 GISL trial. Bone marrow mononuclear cells (BMMCs) stained with anti-CD34 antibody and Annexin V, were evaluated by flow cytometry before starting chemotherapy, 30 days after completing chemotherapy and after 6 months. Results are expressed as the percentages of BMMCs positive to anti-CD34, to Annexin V or to both. Fourteen patients treated with ABVD, 11 with COPPEBVCAD and 13 with BEACOPP were evaluated before and 30 days after treatment. Late assessments were made in 6, 7 and 8 of them, respectively. No differences were found among the pretherapeutic flow cytometry findings in relation to the staging characteristics (marrow involvement included). All the regimens increased the apoptotic fraction of the whole mononuclear bone marrow cells (COPPEBVCAD did so significantly) and increased the CD34+ compartment (with significant early differences after ABVD and BEACOPP, tending to late persistence for ABVD, only). All the regimens increased the apoptotic CD34+ cells within the whole BMMC population (significantly after BEACOPP), although with a general trend to decrease in their percentage within the CD34+ compartment over time, even after the most dose-dense regimens. Based on the variations induced in the apoptotic fraction of all mononuclear and CD34+ cells, ABVD was the least toxic regimen and COPPEBVCAD the most toxic one.

Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma / Gobbi, P. G.; Valentino, F.; Danova, M.; Morabito, F.; Rovati, B.; Mammi, Caterina; Gentile, M.; Merli, F.; Stelitano, C.; Luminari, Stefano; Quintana, G.; Iannitto, E.; Brugiatelli, M.; Federico, Massimo. - In: ONCOLOGY REPORTS. - ISSN 1021-335X. - STAMPA. - 21:4(2009), pp. 1029-1035. [10.3892/or_00000320]

Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma

MAMMI, Caterina;LUMINARI, Stefano;FEDERICO, Massimo
2009

Abstract

The aim of this study was to evaluate the apoptotic damage to bone marrow cells caused by three chemotherapy regimens for advanced Hodgkin's lymphoma, ABVD, COPPEBVCAD and BEACOPP, which were randomly administered in the HD 2000 GISL trial. Bone marrow mononuclear cells (BMMCs) stained with anti-CD34 antibody and Annexin V, were evaluated by flow cytometry before starting chemotherapy, 30 days after completing chemotherapy and after 6 months. Results are expressed as the percentages of BMMCs positive to anti-CD34, to Annexin V or to both. Fourteen patients treated with ABVD, 11 with COPPEBVCAD and 13 with BEACOPP were evaluated before and 30 days after treatment. Late assessments were made in 6, 7 and 8 of them, respectively. No differences were found among the pretherapeutic flow cytometry findings in relation to the staging characteristics (marrow involvement included). All the regimens increased the apoptotic fraction of the whole mononuclear bone marrow cells (COPPEBVCAD did so significantly) and increased the CD34+ compartment (with significant early differences after ABVD and BEACOPP, tending to late persistence for ABVD, only). All the regimens increased the apoptotic CD34+ cells within the whole BMMC population (significantly after BEACOPP), although with a general trend to decrease in their percentage within the CD34+ compartment over time, even after the most dose-dense regimens. Based on the variations induced in the apoptotic fraction of all mononuclear and CD34+ cells, ABVD was the least toxic regimen and COPPEBVCAD the most toxic one.
21
4
1029
1035
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma / Gobbi, P. G.; Valentino, F.; Danova, M.; Morabito, F.; Rovati, B.; Mammi, Caterina; Gentile, M.; Merli, F.; Stelitano, C.; Luminari, Stefano; Quintana, G.; Iannitto, E.; Brugiatelli, M.; Federico, Massimo. - In: ONCOLOGY REPORTS. - ISSN 1021-335X. - STAMPA. - 21:4(2009), pp. 1029-1035. [10.3892/or_00000320]
Gobbi, P. G.; Valentino, F.; Danova, M.; Morabito, F.; Rovati, B.; Mammi, Caterina; Gentile, M.; Merli, F.; Stelitano, C.; Luminari, Stefano; Quintana, G.; Iannitto, E.; Brugiatelli, M.; Federico, Massimo
File in questo prodotto:
File Dimensione Formato  
Bone marrow.....pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 276.5 kB
Formato Adobe PDF
276.5 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/622926
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact